Advertising cosmetic injectables in Australia: what actually holds up to review

Where the prescription-only line sits

Botulinum toxin products and most dermal fillers are Schedule 4 medicines. Under section 42DL of the Therapeutic Goods Act, advertising prescription-only medicines to the public is prohibited. In practice that removes brand names, active ingredients, product images, unit pricing tied to the substance, and language that clearly implies a specific product.

The prohibition is not limited to obvious mentions. The TGA looks at the overall impression of a piece, including hashtags, emojis, before-and-after imagery paired with product cues, and third-party content the clinic shares or amplifies. If a reasonable member of the public would understand the reference, the reference has been made.

What the brand can still own

A cosmetic clinic can promote the consultation, the practitioner, the assessment process, the service categories the market already understands (for example, anti-wrinkle injections and dermal filler treatments as general categories), aftercare, and the standards the clinic works to. That is enough surface for a distinctive brand when it is designed deliberately rather than retro-fitted around a compliance edit.

Positioning around service quality, safety practice, clinical judgement and patient education tends to hold up under review because it does not depend on product claims. It also compounds—each campaign reinforces the same brand truth instead of being rewritten every time the substantiation shifts.

Before-and-after imagery, testimonials and reviews

Testimonials about clinical aspects of a regulated health service are restricted under the National Law, and Ahpra's cosmetic surgery and non-surgical cosmetic procedure guidance is explicit about how imagery and patient stories may be used. Before-and-after photographs are not banned, but they must be genuine, comparable in lighting and posture, dated, consented, and free of claims the images cannot support.

Reviews the clinic solicits, edits, filters or incentivises can breach both Ahpra guidance and ACCC rules on misleading conduct. A safer default is a documented review policy: what is invited, what is displayed, what is removed and why. Keep the record; it is the evidence that decides most complaints.

• No brand or product names in public-facing content
• Testimonials that reference clinical outcomes stay out
• Before-and-after imagery uses matched, dated, consented photos
• A written review policy with a retention log

Build a claim library the clinic can defend

Treat approved claims as an asset. A single source of truth—what may be said about each service, with the evidence attached and the reviewer named—removes most of the friction between marketing and clinical. It also shortens the review cycle, because new work is assembled from approved parts instead of drafted from scratch.

This article is general information, not legal or medical advice. The correct approach depends on the service, the audience and the channel; obtain specialist advice where the risk is material.